Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission
- Assess the tolerability of autologous dendritic cell vaccine in patients with acute
myelogenous leukemia in complete remission.
- Evaluate the emergence of an immune response.
- Determine the relapse rate.
- Assess the occurrence of residual disease.
OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by
autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.
Allocation: Non-Randomized, Primary Purpose: Treatment
Adverse events at 6 months
Christian Chabannon, MD, PhD
United States: Federal Government